Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 8, 2017
-
Nov 2, 2017During the third quarter, the Company announced positive top-line results from its Phase 3 CONVERT Study of ALIS (amikacin liposome inhalation suspension) in patients with NTM lung disease caused by MAC, a rare, progressive, destructive lung infection
-
Sep 11, 2017
-
Sep 5, 2017Study met primary endpoint of culture conversion (p < 0.0001)
-
Aug 3, 2017On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month
-
May 15, 2017Paolo Tombesi named as Chief Financial Officer
-
May 3, 2017Advancing Toward Top-Line Results from CONVERT Study in 2H 2017
-
Feb 23, 2017On Track to Report Top-Line Results from CONVERT Study in 2H 2017
-
Nov 3, 2016Enrollment objective achieved in phase 3 CONVERT study
